Summary & Overview
HCPCS J9165: Injection, diethylstilbestrol diphosphate, 250 mg
HCPCS Level II code J9165 denotes an injection of diethylstilbestrol diphosphate, 250 mg, used to bill for administration of this specific injectable agent. Nationally, precise HCPCS coding for parenteral drugs supports accurate claims processing, clinical documentation, and tracking of specialized therapies administered in outpatient and office-based settings. This code is relevant for hospitals, physician practices, and infusion centers that provide injectable oncology or endocrine-related treatments.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise summary of what the code represents, typical sites of service, and the payer landscape addressed in the analysis. The publication includes benchmark considerations for reimbursement and claim handling, notes on billing practice patterns, and clinical context for the injectable service. Where available, policy updates and payer-specific handling are summarized to inform coding and billing workflows. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J9165 represents an injection of diethylstilbestrol diphosphate, 250 mg. This code is used to bill for the specific pharmaceutical administration described and reflects a parenteral drug service.
-
Service type: Parenteral drug administration (injectable chemotherapy/endocrine agent)
-
Typical site of service: Hospital outpatient departments, physician offices, and infusion centers where injectable oncology or endocrine therapies are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult male or female with hormone-responsive carcinoma being managed in an outpatient oncology clinic or hospital outpatient infusion center. The patient presents for intramuscular or intralesional administration of J9165 (diethylstilbestrol diphosphate, 250 mg) as part of systemic hormone therapy or palliative management when indicated by oncologic treatment protocols. The clinical workflow includes verification of order and indication, review of allergies and prior medications, informed consent, baseline vital signs and performance status assessment, preparation of the drug by pharmacy per sterile technique, verification of lot and dose, administration by an authorized clinician (oncology nurse or physician) with appropriate route documentation, observation for immediate adverse reactions, and documentation of dose, lot number, administration site, and any patient response. Billing typically occurs under the HCPCS Level II code J9165 with applicable modifiers reflecting procedural circumstances, and relevant diagnosis coding to support medical necessity is appended to the claim.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work required is substantially greater than typically required. |